MXPA03010510A - Composicion catartica. - Google Patents

Composicion catartica.

Info

Publication number
MXPA03010510A
MXPA03010510A MXPA03010510A MXPA03010510A MXPA03010510A MX PA03010510 A MXPA03010510 A MX PA03010510A MX PA03010510 A MXPA03010510 A MX PA03010510A MX PA03010510 A MXPA03010510 A MX PA03010510A MX PA03010510 A MXPA03010510 A MX PA03010510A
Authority
MX
Mexico
Prior art keywords
cathartic
composition
cathartic composition
cleansing
relieving
Prior art date
Application number
MXPA03010510A
Other languages
English (en)
Spanish (es)
Inventor
Ueno Ryuji
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of MXPA03010510A publication Critical patent/MXPA03010510A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MXPA03010510A 2001-05-18 2002-05-17 Composicion catartica. MXPA03010510A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29163501P 2001-05-18 2001-05-18
PCT/JP2002/004768 WO2002094274A1 (en) 2001-05-18 2002-05-17 Cathartic composition

Publications (1)

Publication Number Publication Date
MXPA03010510A true MXPA03010510A (es) 2004-03-02

Family

ID=23121127

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010510A MXPA03010510A (es) 2001-05-18 2002-05-17 Composicion catartica.

Country Status (18)

Country Link
US (2) US6956056B2 (https=)
EP (1) EP1389116B1 (https=)
JP (1) JP4597481B2 (https=)
KR (1) KR100867295B1 (https=)
CN (1) CN1273140C (https=)
AR (3) AR035242A1 (https=)
AT (1) ATE387204T1 (https=)
AU (1) AU2002307725B2 (https=)
BR (1) BR0209863A (https=)
CA (1) CA2445651C (https=)
DE (1) DE60225266T2 (https=)
DK (1) DK1389116T3 (https=)
ES (1) ES2301681T3 (https=)
MX (1) MXPA03010510A (https=)
NZ (1) NZ529406A (https=)
PT (1) PT1389116E (https=)
TW (2) TWI324589B (https=)
WO (1) WO2002094274A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
NZ539582A (en) * 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
US7049319B2 (en) 2003-09-23 2006-05-23 Semaan Abboud Colon cleansing composition and method
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US20070071793A1 (en) * 2005-09-23 2007-03-29 Leon Clark Cure for prostate enlargement frequency of urination and cancer
KR101437302B1 (ko) * 2006-02-07 2014-09-02 가부시키가이샤 아루떼꾸 우에노 프로스타글란딘 유도체의 제조 방법
CN102050808B (zh) * 2009-11-02 2014-03-12 上海天伟生物制药有限公司 一种前列腺素中间体的制备方法
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
JP6957610B2 (ja) 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ
US10457623B1 (en) * 2018-07-13 2019-10-29 Chirogate International Inc. Process for the preparation of Lubiprostone and intermediates thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1396206A (en) * 1972-04-27 1975-06-04 Upjohn Co Prostaglandins and the preparation thereof
ZA744581B (en) * 1973-07-20 1975-07-30 Upjohn Co Prostoglandin analogs
US3969376A (en) * 1973-07-20 1976-07-13 The Upjohn Company 13,14-Dihydro-16-fluoro prostaglandin E1 analogs
US3969379A (en) * 1975-02-21 1976-07-13 The Upjohn Company 13,14-Dihydro-16-fluoro prostaglandin A1 analogs
US3969381A (en) * 1975-02-21 1976-07-13 The Upjohn Company 13,14-Dihydro-16-fluoro prostaglandin B1 analogs
GB8305697D0 (en) * 1983-03-02 1983-04-07 Erba Farmitalia Pharmaceutical compositions
EP0153858A3 (en) * 1984-02-29 1985-12-11 The Upjohn Company The therapeutic use of prostaglandins
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
WO1997047595A1 (en) * 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers

Also Published As

Publication number Publication date
JP4597481B2 (ja) 2010-12-15
EP1389116A1 (en) 2004-02-18
JP2004529960A (ja) 2004-09-30
TW200944210A (en) 2009-11-01
US20030022933A1 (en) 2003-01-30
KR20040020055A (ko) 2004-03-06
EP1389116B1 (en) 2008-02-27
AR035242A1 (es) 2004-05-05
CA2445651A1 (en) 2002-11-28
ES2301681T3 (es) 2008-07-01
ATE387204T1 (de) 2008-03-15
AU2002307725B2 (en) 2008-07-10
CN1273140C (zh) 2006-09-06
DK1389116T3 (da) 2008-06-23
AR098744A2 (es) 2016-06-08
NZ529406A (en) 2005-09-30
DE60225266T2 (de) 2009-03-19
US20050261375A1 (en) 2005-11-24
TWI324589B (en) 2010-05-11
US7459583B2 (en) 2008-12-02
TWI320711B (en) 2010-02-21
BR0209863A (pt) 2004-06-08
KR100867295B1 (ko) 2008-11-06
WO2002094274A1 (en) 2002-11-28
AR110149A2 (es) 2019-02-27
PT1389116E (pt) 2008-04-11
US6956056B2 (en) 2005-10-18
CA2445651C (en) 2011-08-09
DE60225266D1 (de) 2008-04-10
CN1509176A (zh) 2004-06-30

Similar Documents

Publication Publication Date Title
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
MXPA03010510A (es) Composicion catartica.
IL245955A0 (en) Immunogenic preparations for the prevention and treatment of inflammatory bowel disease
MY136707A (en) Thrombopoietin mimetics
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
IL114641A (en) Pharmaceutical compositions containing dispersible fluoxetine
HU9601218D0 (en) Distamycin a analogue utilizable as antitumoral and antiviral medicines
NO953187D0 (no) Imidazopyridiner og deres anvendelse ved behandling av mave-tarm-sykdommer
IL136591A0 (en) Nasal solutions
GB0012362D0 (en) Chemical compounds
NZ503308A (en) Alpha-ketoamide multicatalytic protease inhibitors
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
EP1900802A3 (en) Toilet bar having a latent acidifier
CA2443285A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
IL155194A0 (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
MXPA03011128A (es) Composicion de sabor y fragancia.
AP2049A (en) Medicament containing activated antithrombin III
DE60205629D1 (en) Akarizidpulver
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
EP1166789A3 (en) Arsenolite containing angiogenesis inhibitor
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
MD1473G2 (ro) Remediu antiherpetic
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
MXPA03010821A (es) Composiciones de aroma y fragancias.

Legal Events

Date Code Title Description
FG Grant or registration